Allergan tries to assuage shareholder fears over Restasis

(Reuters) - Allergan Plc on Wednesday tried to reassure shareholders after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis, downplaying the importance of the loss of revenue from the drug.